These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
545 related articles for article (PubMed ID: 29677483)
1. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors. Sun W; Hu S; Fang S; Yan H Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
5. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling. Adel M; Serya RAT; Lasheen DS; Abouzid KAM Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents. Ghith A; Youssef KM; Ismail NSM; Abouzid KAM Bioorg Chem; 2019 Mar; 83():111-128. PubMed ID: 30343204 [TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation. Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176 [TBL] [Abstract][Full Text] [Related]
8. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701 [TBL] [Abstract][Full Text] [Related]
9. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase. Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324 [TBL] [Abstract][Full Text] [Related]
12. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors. Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents. Qi H; Chen L; Liu B; Wang X; Long L; Liu D Bioorg Med Chem Lett; 2014 Feb; 24(4):1108-10. PubMed ID: 24456902 [TBL] [Abstract][Full Text] [Related]
14. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors. Shi L; Wu TT; Wang Z; Xue JY; Xu YG Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347 [TBL] [Abstract][Full Text] [Related]
15. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking. Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861 [TBL] [Abstract][Full Text] [Related]
16. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965 [TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents. Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]